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Chronic enteropathies are a group of disorders that cause gastrointestinal tract inflammation and per-
sistent or recurrent signs of gastrointestinal tract dis-
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Objective—To characterize mucosal gene expression in dogs with chronic enteropathy 
(CE).
Animals—18 dogs with CE and 6 healthy control dogs.
Procedures—Small intestinal mucosal biopsy specimens were endoscopically obtained 
from dogs. Disease severity in dogs with CE was determined via inflammatory bowel index 
scores and histologic grading of biopsy specimens. Total RNA was extracted from biopsy 
specimens and microchip array analysis (approx 43,000 probe sets) and quantitative reverse 
transcriptase PCR assays were performed.
Results—1,875 genes were differentially expressed between dogs with CE and healthy 
control dogs; 1,582 (85%) genes were downregulated in dogs with CE, including neuro-
tensin, fatty acid–binding protein 6, fatty acid synthase, aldehyde dehydrogenase 1 family 
member B1, metallothionein, and claudin 8, whereas few genes were upregulated in dogs 
with CE, including genes encoding products involved in extracellular matrix degradation 
(matrix metallopeptidases 1, 3, and 13), inflammation (tumor necrosis factor, interleukin-8, 
peroxisome proliferator–activated receptor γ, and S100 calcium-binding protein G), iron 
transport (solute carrier family 40 member 1), and immunity (CD96 and carcinoembryonic 
antigen–related cell adhesion molecule [CEACAM] 18). Dogs with CE and protein-losing 
enteropathy had the greatest number of differentially expressed genes. Results of quantita-
tive reverse transcriptase PCR assay for select genes were similar to those for microchip 
array analysis.
Conclusions and Clinical Relevance—Expression of genes encoding products regulating 
mucosal inflammation was altered in dogs with CE and varied with disease severity.
Impact for Human Medicine—Molecular pathogenesis of CE in dogs may be similar to 
that in humans with inflammatory bowel disease. (Am J Vet Res 2012;73:1219–1229)
ease in dogs. The most common causes include ad-
verse gastrointestinal tract reaction to food, idiopathic 
IBD, and antimicrobial-responsive enteropathy.1–4 The 
pathogenesis of CE in dogs likely involves several fac-
tors including host genetics, intestinal microenviron-
ment (bacteria and diet), immune system function, and 
environmental triggers of intestinal inflammation.1,5–7 
Strategies for diagnosis of CE include extensive evalua-
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AbbreviAtions
CD Crohn’s disease
CE Chronic enteropathy
CIBDAI Canine inflammatory bowel disease 
   activity index
GO Gene ontology
IBD Inflammatory bowel disease
NF-κB Nuclear factor-κB
PLE Protein-losing enteropathy
QRT-PCR Quantitative reverse transcriptase PCR
UC Ulcerative colitis
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tion of patients to detect underlying diseases and histo-
logic evaluation of intestinal mucosal biopsy specimens 
for detection of lymphocytic-plasmacytic, eosinophilic, 
or granulomatous inflammation.1,2
Dysregulated gene expression is important in the 
pathogenesis of CEs in humans, including IBD.8 Vari-
ous genes encoding for proteins involved in fatty acid 
absorption and synthesis have different levels of expres-
sion in the ileum and colon of humans with CD and 
UC.9 Results of another study10 in which microchip ar-
ray analysis of mRNA from mucosal biopsy specimens 
was performed indicate genes encoding for enzymes 
responsible for detoxification (eg, cytochrome P450) 
are downregulated in cells of the colonic mucosa of hu-
mans with IBD. Genes encoding for chemokines, mark-
ers of neutrophil activation, and anti-inflammatory 
factors are upregulated in humans with CE.11,12 More-
over, disturbances in expression of genes encoding for 
proteins involved in innate or adaptive immunity, de-
toxification, and nuclear transcription are important in 
the pathogenesis of mucosal inflammation in mice with 
experimentally induced colitis.13,14
The objectives of the study reported here were to de-
termine gastrointestinal mucosal gene expression patterns 
in dogs with CE, compare results with those for healthy 
control dogs, and determine whether gene expression dif-
fers among dogs with CE of various severities. In addition, 
expression of genes in dogs with CE was compared with 
that reported for humans with IBD.
Materials and Methods
Animals—Eighteen dogs with CE were included 
in the study. Criteria for selection of dogs with CE 
included a history of chronic vomiting, diarrhea, or 
weight loss of at least 6 weeks’ duration, exclusion of 
identifiable underlying disorders (via performance of a 
thorough laboratory diagnostic evaluation), and histo-
pathologic evidence of gastrointestinal mucosal inflam-
mation consistent with a diagnosis of idiopathic CE. 
Prior to enrollment, dogs had been fed an elimination 
diet exclusively for 3 weeks followed by treatment with 
metronidazole (10 mg/kg, PO, q 12 h for 3 weeks); dogs 
selected for the study had failed to improve with either 
treatment. All medications were discontinued at least 
2 weeks before collection of gastrointestinal mucosal 
specimens. Disease severity was determined by use of 
the CIBDAI,15 which included assessment of the follow-
ing 6 variables: attitude and activity, appetite, vomiting, 
fecal consistency, fecal frequency, and weight loss. After 
summation of scores for each of the 6 variables, a total 
composite score was determined, which indicated clini-
cally unimportant (score, 0 to 3), mild (score, 4 to 5), 
moderate (score, 6 to 8), or severe (score, 9 or greater) 
clinical signs of CE.
Six mixed-breed dogs owned by Iowa State Uni-
versity were included in the healthy control group. 
Control dogs were judged to be healthy on the basis of 
unremarkable physical examination, CBC, serum bio-
chemical analysis, urinalysis, and direct or indirect fe-
cal evaluation (for detection of parasites) results. None 
of the healthy control dogs had signs of gastrointestinal 
tract disease during the 6 weeks prior to the start of the 
study.
Approval to conduct the study was obtained from 
the Iowa State University Institutional Animal Care 
and Use Committee. Owners of dogs with CE provided 
informed written consent prior to enrollment of those 
dogs in the study.
Collection of tissue biopsy specimens—Food 
was withheld from dogs for 12 hours prior to collec-
tion of tissue specimens. Mucosal biopsy specimens 
were endoscopically obtained from the stomach and 
duodenum of each dog for histologic examination 
as part of a standard esophagogastroduodenoscopy 
protocol performed at Iowa State University. Gastric 
biopsy specimens were obtained for microscopic 
evaluation to detect gastric mucosal inflammation 
attributable to causes other than CE (eg, Helicobacter 
spp–associated gastritis). Each dog underwent a 
standard anesthetic protocol; butorphanol was ad-
ministered IV as a preanesthetic agent, propofol was 
administered IV as an induction agent, and isoflurane 
(administered at a concentration of 2% to 3% in oxy-
gen delivered with an inhalation gas delivery system) 
was used to maintain anesthesia. Ten to 12 mucosal 
biopsy specimens were obtained from the proximal 
to middle portions of the duodenum of each dog. 
Four mucosal biopsy specimens were obtained from 
each colonic segment (ascending, transverse, and 
descending) of 4 dogs that underwent colonoscopy. 
Colonoscopy was performed in these 4 dogs because 
they had clinical signs of enterocolitis with inflam-
mation of both the small and large intestines. Three 
duodenal mucosal biopsy specimens from each dog 
were placed in a commercial liquid RNA preserva-
tivea immediately after collection and kept at −80°C 
until isolation of RNA. The remaining specimens 
were placed in 10% neutral-buffered formalin, rou-
tinely processed, and stained with H&E for histolog-
ic evaluation. Sections of intestinal mucosal biopsy 
specimens were scored by use of standardized crite-
ria to determine type and amount of inflammatory 
cell infiltrate and architectural changes in tissue.16 
All intestinal mucosal biopsy specimen sections were 
evaluated by a board-certified veterinary pathologist 
(MRA) with experience in gastrointestinal pathology.
RNA extraction and cDNA synthesis—Total RNA 
was extracted from 2 intestinal mucosal biopsy speci-
mens of each dog by use of a commercial RNA extrac-
tion kitb in accordance with the manufacturer’s protocol 
for extraction of RNA from animal tissue. Purity and 
integrity of RNA were assessed via a bioanalyzer with a 
reagent set.c Control samples that did not undergo re-
verse transcription and had nuclease-free water instead 
of RNA were prepared. First-strand cDNA was synthe-
sized by use of random hexamers and oligo(dT) prim-
ersd in accordance with the manufacturer’s instructions. 
None of the RNA samples had evidence of genomic 
DNA after amplification.
Microchip array analysis—Total RNA was trans-
ported to the University of Minnesota Biomedical 
Genomics Center Microarray Facility for labeling, hy-
bridization, and acquisition of images. Microchip ar-
ray analysis was performed with an array platform.e 
Control samples included 4 spiked control samples for 
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labeling (lys, phe, thr, and dap genes of Bacilus subti-
lis), 4 exogenous spiked control samples for hybridiza-
tion (bioB, bioC, and bioD genes of E coli and the cre 
gene of the P1 bacteriophage), and the housekeeping 
genes glyceraldehyde 3-phosphate dehydrogenase and 
β-actin for normalization of gene expression data. The 
order in which samples were prepared was determined 
by use of a computer-generated randomization proce-
dure prior to processing to avoid systematic bias. Hy-
bridization reactions were performed with reagentsf in 
accordance with the manufacturer’s instructions and as 
previously described.17 After hybridization, microchips 
were washed and stained with a streptavidin-conjugat-
ed phycoerthyrin dye enhanced with biotinylated goat 
anti-streptavidin antibody via a wash and stain stationg 
and associated software. Images of microchips were ac-
quired by use of a scanning system.h
The microchip arraye included 43,036 probes to 
simultaneously detect approximately 18,000 Canis fa-
miliaris mRNA or expressed sequence tag–based tran-
scripts and > 20,000 nonredundant predicted genes. 
Sequences in the microchip array were obtained from 
C familiaris UniGene build No. 11 (April 2005); Gen-
Bank mRNA sequences up to April 15, 2005; and gene 
predictionsi from the Boxer genome.j Each RNA sample 
from each dog was treated as an individual unit for 
analysis.
QRT-PCR assay—To confirm results of microchip 
array analysis, some of the genes with > 3.0-fold dif-
ferences in expression among dogs with CE of vari-
ous severities were assayed with asymmetric cyanine 
dye–based 2-step real-time QRT-PCR assay (Appen-
dix); cDNA prepared from each total RNA sample was 
used. Gene-specific primer sets were designed by use of 
software,k and at least one of the primers in each prim-
er pair spanned a genomic intron. Target sequences in 
cDNA samples were detected with QRT-PCR assay by 
use of a dye mixture.l For normalization of data, ex-
pression of the canine β-glucuronidase gene was used 
as the reference because it had stable expression in in-
testinal mucosal biopsy specimens obtained from dogs 
of all groups.
Prior to analysis of cDNA samples, all QRT-PCR as-
say gene targets were evaluated on a test plate via serial 
dilutions (range, undiluted to 1:100,000) of a mixture 
consisting of an equal portion of each of the 24 (6 con-
trol and 18 CE dogs) study cDNA samples. Results of 
this test plate QRT-PCR assay indicated the cDNA sam-
ple dilution range within which quantitative PCR inhi-
bition was absent and within which standard curves for 
all targets could be reliably generated. Calculation of re-
sults was performed via a spreadsheet softwarem–based 
method.18 Test plate QRT-PCR assay results indicated 
that the cDNA samples had no quantitative PCR–inhib-
itory properties, and a common dilution range (1:5 to 
1:250 [1.319 to 0.0263 ng of cDNA/µL]) for all target 
sequence standard curves was determined by use of the 
spreadsheet softwarem–based method.18
Standard curves with 5 data points were generated 
for each target sequence within the common dilution 
range. Each cDNA sample was diluted to a concentra-
tion of approximately 2.8637 ng/µL before performance 
of QRT-PCR assays so that addition of 6 µL of cDNA 
to each 25-µL assay mixture resulted in a final cDNA 
concentration of 0.6873 ng/µL. This concentration val-
ue had been calculated via the spreadsheet softwarem–
based method as the mean of the first 2 points of each 
target sequence standard curve. The reaction mixture 
also contained forward and reverse primers (500nM 
each; Appendix), nuclease-free water, 3mM MgCl
2
, 
and 500nM (final concentration) free passive refer-
ence dye.n The cDNA samples, control samples without 
template sequences, and standard curve samples were 
placed in duplicate in wells of 96-well QRT-PCR assay 
plates. Plates were placed in a sequence detection sys-
temo and exposed to the following thermoprotocol: 2 
minutes at 50°C, 2 minutes at 95°C, 40 cycles of 15 
seconds at 95°C, and 30 seconds at 60°C, then melt 
curve analysis at 60°C. Cycle values were determined 
at an appropriate threshold for each target sequence 
by use of software,o and relative quantitative analysis 
was performed manually by use of custom spreadsheet 
files.m Sample signals determined to have resulted from 
primer-dimer formation (on the basis of evaluation of 
melt curves) were excluded from data analysis. Cycle 
values for each target sequence in each cDNA sample 
were interpreted by use of the standard curve for each 
of those target sequences. The resulting relative target 
sequence expression values were normalized relative 
to β-glucuronidase expression. Relative expression 
data were calculated by use of an efficiency-corrected 
method.19
Statistical analysis—Data from the 24 (6 control 
and 18 CE dogs) microchip array analyses were nor-
malized by use of the robust multiarray mean normal-
ization method.20 For each of the approximately 43,000 
probe sets on the microchip array, a standard permu-
tation test was applied to the normalized data to test 
for differences in distribution of target sequence ex-
pression between healthy control dogs and dogs with 
CE. Permutation tests yielded a P value for each of the 
probe sets. These P values were converted to q values 
as previously described.21 Genes that had different ex-
pression between groups of dogs and an estimated false 
discovery rate of 1% (q < 0.01) were identified. Only 
results for probe sets having an estimated ≥ 2-fold dif-
ference in expression between groups of dogs were 
evaluated further.
A Fisher exact test was used to identify GO terms 
that were overrepresented among the probe sets for 
genes that were determined to have different expression 
between groups of dogs. One test for overrepresenta-
tion was conducted for each of the GO terms that was 
associated with probe sets with statistically significant 
results; GO annotation information was provided by 
the microarray chip manufacturer.p Functional attribu-
tions of genes were determined via a databaseq with the 
default parameters.
To determine whether gene expression was associ-
ated with severity of clinical disease, microchip array 
analysis results for 17 genes that had > 3.0-fold differ-
ences in expression among dogs with CE of various 
severities (on the basis of CIBDAI values) were sta-
tistically compared. These genes included chemokine 
ligand 13, aldehyde dehydrogenase 1 family member 
B1, metallothionein, tachykinin precursor 1, solute car-
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rier family 40 member 1, RNase A family 1, caspase 3, 
CD96 molecule, granzyme B, matrix metallopeptidase 
1, fatty acid–binding protein 6, glucagon, claudin 8, 
S100 calcium-binding protein G, cell division cycle as-
sociated 3, peroxisome proliferator–activated receptor 
γ, and neurotensin. An ANOVA overall F test was used 
to identify significant differences among results for 
dogs with various severities of CE (dogs with moderate 
CE, dogs with severe CE but not PLE, dogs with PLE) 
and healthy control dogs; this was intended to identify 
associations between gene expression and disease sever-
ity. This analysis was performed separately for each gene. 
Then, pairwise comparisons were performed between 
gene expression values for each group of dogs for genes 
with an overall F test value that was significant (P < 0.05).
Gene expression in mucosal biopsy specimens 
obtained from dogs with CE in the present study de-
termined with microchip array analysis was compared 
with expression of genes in humans with IBD deter-
mined in other studies. Results of gene expression pro-
files in humans with CD or UC were obtained via lit-
erature searches for manuscripts published from 1998 
through 2010. 
Results
Demographics and clinical characteristics of 
dogs—Of the 18 dogs with CE, 8 were males (3 sexu-
ally intact and 5 neutered) and 10 were females (1 sexu-
ally intact and 9 neutered). Mean age of these dogs was 
7.2 years (range, 3 to 11 years). Breeds included mixed 
(n = 5), German Shepherd Dog (2), and 1 each of Aus-
tralian Shepherd Dog, Cocker Spaniel, English Bulldog, 
Labrador Retriever, Jack Russell Terrier, Gordon Setter, 
Keeshond, German Shorthair Pointer, Yorkshire Terrier, 
Shih Tzu, and Beagle. All dogs with CE had moderate 
(n = 10) to severe (8) disease; mean CIBDAI score was 
7.8 (range, 6 to 12). Five of the 8 dogs with severe CE 
had panhypoproteinemia (mean serum albumin con-
centration, 1.7 g/dL [range, 1.2 to 1.9 g/dL]; mean to-
tal protein concentration, 3.5 g/dL [range, 3.0 to 3.9 
g/dL]), which was consistent with a diagnosis of PLE; 
these dogs had a mean CIBDAI score of 8.6. Abnormali-
ties  of duodenal mucosa (ie, increased granularity, fri-
ability, or erosions) were endoscopically observed in all 
18 dogs with CE. Four of these dogs also underwent 
colonoscopy; each of these dogs had colonic erosions 
and areas of colonic mucosa that were friable. Histolog-
ic examination of intestinal mucosal biopsy specimens 
indicated 8 dogs had mild and 10 dogs had moderate to 
severe inflammatory lesions (Figure 1).
Mean age of the 6 healthy control dogs was 4.3 
years (range, 3 to 6 years). Results of laboratory tests, 
endoscopic examinations, and histologic examination 
of mucosal biopsy specimens obtained from these con-
trol dogs were unremarkable.
Gene expression determined via microchip ar-
ray—Target gene expression was significantly differ-
ent between healthy control dogs and dogs with CE for 
1,875 of the probe sets. Healthy control dogs and dogs 
with CE had significantly different expression of genes 
associated with protein synthesis and transport, cell 
replication, intracellular organelles, and extracellular 
matrix degradation (data not shown). Selective filter-
Figure 1—Photomicrographs of representative small intestinal mu-
cosal biopsy specimens endoscopically obtained from dogs with 
CE. A—Notice moderate diffuse lymphocytic-plasmacytic infiltra-
tion in the lamina propria and marked dilation of 2 crypts that con-
tain eosinophilic material, numerous neutrophils, and cell debris 
(crypt abscess). These crypts are lined by thin elongate cells. B—
Notice severe villous atrophy and lymphocytic-plasmacytic enteri-
tis. Intestinal villi are short and wide, and some have dilated lac-
teals surrounded by dense infiltrates of lymphocytes and plasma 
cells. Numerous intraepithelial lymphocytes are present. C—No-
tice a focally extensive mucosal ulcer covered by neutrophils and 
cell debris. There is a dense infiltrate of lymphocytes, plasma cells, 
and macrophages deep to the ulcer. H&E stain; bars = 200 µm.
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ing (fold enrichment ≥ 1.3 and false discovery rate < 
1%) of genes indicated that expression of most differen-
tially expressed genes was lower in intestinal mucosal 
biopsy specimens obtained from dogs with CE versus 
those obtained from healthy control dogs. Of the 1,875 
genes, expression of 1,582 (84%) was lower in intesti-
nal mucosal biopsy specimens obtained from dogs with 
CE versus those obtained from healthy control dogs, in-
cluding genes with annotations indicating associations 
with mucosal homeostasis, mitosis and cell cycle, and 
cell-to-cell signaling. Few genes had significantly high-
er expression in mucosal biopsy specimens obtained 
from dogs with CE versus those obtained from control 
dogs; these included genes encoding for the matrix me-
tallopeptidases and proteins associated with inflamma-
tion and immune function.
Results for select genes with significantly different 
expression between dogs with CE and healthy control 
dogs were summarized (Table 1). Neurotensin was the 
most highly downregulated (compared with expression 
   Fold difference
Gene name Abbreviation Function of protein in expression*
RNase A family 1 Ribonucleic acid SE1 RNA hydrolysis 57
Matrix metallopeptidase 1 MMP1 Extracellular matrix degradation 11
S100 calcium-binding protein G S100G Calcium transport and activity 11
Solute carrier family 40 member 1 SLC40A Iron transport 11
Peroxisome proliferator–activated receptor γ PPARG Regulates NF-κβ pathway 4
Tumor necrosis factor TNF Promotes inflammation 3
Interleukin-8 IL-8 Induces chemotaxis 3
   
CD96 molecule CD96 Adaptive and innate immunity 3
Caspase 3 CASP3 Cellular apoptosis 3
Granzyme B GZMB Cytotoxic T lymphocyte–mediated apoptosis 3
Neurotensin NTS Neuropeptide signaling –92
Glucagon GCG Counters insulin, cell proliferation –67
Aldehyde dehydrogenase 1 ALDH1B1 Metabolizes alcohol –16
  family member B1
Regenerating islet-derived 3 gamma REG3G Promotes inflammation –8
   
Fatty acid–binding protein 6 FABP6 Fatty acid uptake and transport –13
Tachykinin precursor 1 TAC1 Gastrointestinal tract neuropeptide –8
Metallothionein MTIE Barrier function –7
Claudin 8 CLDN8 Tight junction protein –6
Chemokine ligand 13 CXCL13 B-cell chemoattractant –4
Cell division cycle associated 3 Centers for Disease Control and Promotes mitosis –4
   Prevention A3
Fatty acid synthase FASN Fatty acid synthesis –3
*Results are expressed relative to expression of genes in intestinal mucosal biopsy specimens endoscopically obtained from 6 healthy control 
dogs. Expression of all genes listed is significantly (P < 0.05) different between dogs with CE and healthy control dogs.
Table 1—Expression of select genes in intestinal mucosal biopsy specimens endoscopically obtained from 18 dogs with CE as 
determined with microchip array analysis.
   Pairwise comparison 
Gene Abbreviation PC PS PM SC
Chemokine ligand 13 CXCL13 < 0.001* 0.03* 0.04* 0.04*
Aldehyde dehydrogenase 1 ALDH1B1 < 0.001* 0.03* 0.05 0.10
  family member B1
Metallothionein MT1E < 0.001* 0.03* 0.04* 0.08
Tachykinin precursor 1 TAC1 < 0.001* 0.03* 0.03* 0.07
Solute carrier family 40 SLC40A < 0.001* 0.03* 0.04* 0.11
  member 1
RNase A family 1 Ribonucleic acid SE1 < 0.001* 0.03* 0.04* 0.09
     
Caspase 3 CAP3 0.002* 0.11 0.16 0.24
CD96 molecule CD96 0.008* 0.27 0.10 0.19
Granzyme B GZMB 0.03* 0.56 0.08 0.20
Matrix metallopeptidase 1 MMP1 0.005* 0.03* 0.06 0.73
Fatty acid–binding protein 6 FABP6 < 0.001* 0.07 0.25 0.09
Data are P values for pairwise comparisons of expression of genes. Results for 17 genes with > 3.0-
fold different expression among dogs with CE of various severities (moderate CE, severe CE but not PLE, 
and PLE; determined by use of the CIBDAI15) were compared. Genes with significantly (P < 0.05) different 
expression among dogs with various severities of CE and healthy control dogs were selected for further 
analysis. Expression of these genes was compared in a pairwise manner between groups of dogs.
*Expression of gene is significantly (P < 0.05) different between the groups of dogs for which results are 
compared in the column.
PC = Dogs with PLE versus healthy control dogs. PM = Dogs with PLE versus dogs with moderate CE. PS = 
Dogs with PLE versus dogs with severe CE but not PLE. SC = Dogs with severe CE but not PLE versus healthy 
control dogs.
Table 2—Results of pairwise comparisons of gene expression in intestinal mucosal biopsy specimens 
endoscopically obtained from 18 dogs with CE of various severities and 6 healthy control dogs.
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Figure 2—Mean ± SEM expression of select genes in intestinal mucosal biopsy samples endoscopically obtained from 18 dogs with 
CE (light gray bars) and 6 healthy control dogs (dark gray bars). Values were determined via QRT-PCR assay. Expression values are nor-
malized relative to expression of β glucuronidase. Expression of each of the genes is significantly (P < 0.05) different between groups 
of dogs. ANP32 = ANP32 family member A. CASP3 = Caspase 3. CLCN = Chloride channel 3. FBL = Fibrillarin. GZMB = Granzyme B. 
MMP1 = Matrix metallopeptidase 1.
    Relative gene 
    expression in 
Gene function and abbreviation Name of gene Type of IBD References  dogs with CE†
Immune and inflammatory response    
  CD96 CD96 molecule CDa 63 3
  IL-8 Interleukin-8 CD and UC 8 and 63 3
  TNF Tumor necrosis factor CDc and UCc 60 and 62 3
  CXCL13 CXCL13 — — –4
  PPARG Peroxisome proliferator–activated receptor γ CDa 63 4
    
Cell proliferation and growth    
  REG3G Regenerating islet-derived 3 gamma UC 8 and 60 –8
  Ribonucleic acid SE1 RNase family genes UC 8 57
  GCG Glucagon CD 8 and 63 –67
  Centers for Disease Control and Cell division cycle associated protein 3 — — –4
    Prevention A3
  S100G S100 calcium-binding protein G CD and UC 8 and 63 11
  CASP3 Caspase 3 — — 3
  GZMB Granzyme B CDc 61 3
    
Cell structure and permeability    
  MT1E Metallothionein 1E UC 8 –7
  MT2A Metallothionein 2A CDa,c 63 –5
  MMP1 Matrix metallopeptidase 1 CD and UC 8 and 63 11
  MMP3 Matrix metallopeptidase 3 CD and UC 8 and 60 3
  MMP13 Matrix metallopeptidase 13 UCb,c 64 4
  CLDN8 Claudin 8 CDa 58 –6
    
Metabolic pathways and transport    
  SLC40A Solute carrier family 40 member 1 CDa 54 11
  ALDH1B1 Aldehyde dehydrogenase 1 family member B1 CDa 58 and 63 –16
  FABP6 Fatty acid–binding protein 6 CD and UC 9 and 58 –13
  — Fatty acid synthase CD and UC 9 –3
  CPO Carboxypeptidase CDa 58 –7
    
  Neuropeptide signaling    
    NTS Neurotensin CDa 58 –92
    TAC1 Tachykinin precursor 1 — — –8
Data are comparisons of mRNA expression values unless otherwise indicated.
*Genes with increased or decreased expression in humans with CD or UC. †Results are expression of genes in dogs with CE relative to 
expression in humans with IBD.
— = Not applicable.
aGene expression results only for humans with CD. bGene expression results only for humans with UC . cResults are for protein expression.
Table 3—Comparison of gene expression in dogs with CE in the present study versus that in humans with IBD* reported by other 
authors.
11-05-0187r.indd   1224 7/20/2012   1:28:57 PM
AJVR, Vol 73, No. 8, August 2012  1225
in healthy control dogs) gene in dogs with CE (expres-
sion 92-fold as low). Other genes significantly down-
regulated in dogs with CE included glucagon (expres-
sion 67-fold as low), aldehyde dehydrogenase 1 family 
member B1 (18-fold as low), and fatty acid–binding 
protein 6 (15-fold as low). Both metallothionein 1E 
and metallothionein 2A genes were downregulated (ex-
pression 7- and 5-fold as low, respectively) in CE dogs, 
compared with gene expression in control dogs. Genes 
with significantly higher expression in dogs with CE 
versus healthy control dogs included RNase A family 
1 (expression 57-fold as high) and matrix metallopep-
tidase 1, solute carrier family 40 member 1, and the 
S100 calcium-binding protein family of genes including 
S100G, S100A2, and S100A10 (11-, 2-, and 2-fold as 
high, respectively).
Gene expression in dogs with various severities 
of CE—Seventeen genes were ˃ 3.0-fold differentially 
expressed (as determined with microchip array analy-
sis) among healthy control dogs and dogs with moder-
ate CE, severe CE but not PLE, and PLE. Of these 17 
genes, expression for 11 was significantly (P < 0.02) 
different among the 4 groups of dogs. Significant dif-
ferences in expression were detected among dogs with 
PLE and those with moderate or severe CE on the ba-
sis of CIBDAI scores (Table 2). Dogs with PLE had 
the highest CIBDAI scores; these dogs had the highest 
number of genes with significantly different expression 
in mucosal biopsy specimens, compared with that in 
healthy control dogs (n = 11 genes), dogs with severe 
CE but not PLE (7), and dogs with moderate CE (5). 
In contrast, only 1 gene was differentially expressed in 
mucosal biopsy specimens obtained from dogs with se-
vere CE that did not have PLE versus those obtained 
from healthy control dogs.
Gene expression determined via QRT-PCR 
assay—Quantitative reverse transcriptase PCR assay 
was performed to determine expression of select genes 
for which significantly different expression was detect-
ed between healthy control dogs and dogs with CE on 
the basis of microchip array analysis. Six genes of inter-
est were selected on the basis that different levels of ex-
pression between groups of dogs had been detected via 
microchip array analysis (acidic [leucine-rich] nuclear 
phosphoprotein 32 family member A and fibrillarin), 
genes encoded for cell-surface molecules (granzyme B, 
caspase 3, and chloride channel 3), or the genes en-
coded for molecules with a putative role in mediating 
intestinal inflammation (granzyme B, caspase 3, and 
matrix metallopeptidase 1). Results of QRT-PCR assay 
for these genes were consistent with results of micro-
chip array analysis (Figure 2).
Gene expression in dogs with CE versus that in 
humans with IBD—Twenty-one of the 25 genes with 
the greatest difference in expression between dogs with 
CE and healthy control dogs are upregulated or down-
regulated in humans with IBD (Table 3). Four of the 
genes with significantly different expression between 
dogs with CE and healthy control dogs (CXCL13, 
cell division cycle associated protein 3, caspase 3, and 
tachykinin precursor 1) are not differentially expressed 
in humans with CD or UC. Of the genes that are 
upregulated in humans with IBD, CD96 molecule, in-
terleukin-8, tumor necrosis factor, peroxisome prolif-
erator–activated receptor γ, RNase A family 1, S100 cal-
cium-binding protein G, caspase 3, granzyme B, matrix 
metallopeptidase 1, matrix metallopeptidase 3, matrix 
metallopeptidase 13, and solute carrier family 40 mem-
ber 1 were upregulated in dogs with CE. Conversely, 9 
of the 21 genes upregulated in humans with IBD were 
downregulated in dogs with CE.
Discussion
Dogs that are genetically predisposed to the most 
prevalent forms of CE, including idiopathic IBD, have 
aberrant immune responses and dysbiotic microbio-
ta.1,3,5,7,22 Chronic enteropathies in dogs are associated 
with abnormalities in mucosal immune cell popula-
tions and cytokine expression, activation of NF-κB, 
and histopathologically detectable intestinal inflam-
mation.1,4,23–27 Results of a recent study22 indicate in-
testinal inflammation is associated with a shift in the 
most prevalent intestinal microbes from gram-positive 
Firmicutes (eg, order Clostridiales) to gram-negative 
bacteria (predominantly Proteobacteria [including En-
terobacteriaceae]). Granulomatous colitis in Boxers is 
associated with invasive Escherichia coli that are simi-
lar to mucosally adherent and invasive E coli associated 
with intestinal inflammation in humans.28 Further-
more, the findings of other investigators that mucosal 
expression of Toll-like receptor-2, -4, and -9 is upregu-
lated in various breeds of dogs29 and that German Shep-
herd Dogs with CE have polymorphisms of Toll-like 
receptor-55 indicate that interaction between intestinal 
microbes and the innate immune system is important. 
Thus, it was our intent to evaluate intestinal mucosal 
gene expression patterns in dogs with CE to identify 
genes that might be involved in CE disease mechanisms 
and to compare results with those reported for humans 
with IBD.
Results of microchip array analysis in the present 
study indicated that expression of > 1,870 genes was 
significantly different between healthy control dogs and 
dogs with CE. The functional importance of these dif-
ferences in gene expression was determined by use of 
annotation-based GO databases. Results of initial GO 
analysis indicated that 42 biological process terms, 30 
cellular components, and 18 molecular function terms 
were significantly overrepresented (false discovery rate 
≤ 1%) among the genes determined to have different 
expression between dogs with CE and healthy control 
dogs (data not shown). Bioinformatics resourcesp were 
used in addition to this computational procedure to 
determine biologically important differences between 
gene expression in dogs with CE versus that in healthy 
control dogs.13,30
Results indicated that a majority (1,582 of 1,875 
[84%]) of differentially expressed genes were down-
regulated (rather than upregulated) in dogs with CE 
in the present study. Neurotensin was the most highly 
downregulated gene in these dogs. Upregulation of 
neurotensin is associated with acute inflammation in 
humans with IBD and repair of injured epithelium (via 
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stimulation of expression of epithelial growth factor re-
ceptor) in rats and mice with experimentally induced 
colitis.31,32 Glucagon and cell division cycle associated 
A3 protein have roles in cellular replication via differ-
ent mechanisms. The cell division cycle-associated A3 
gene in humans encodes a protein that is required for 
controlled entry of cells into mitosis; this protein has 
not been identified in dogs.33 Glucagon-like peptide-2, 
a product of posttranslational processing of progluca-
gon in the intestine, has intestinal growth-promoting 
properties.34 Results of another study35 indicate that 
glucagon-like peptide-2 attenuates intestinal inflam-
mation in rodents with experimentally induced IBD, 
suggesting a potential role for this peptide in treatment 
of IBD in humans. It is possible that dogs with CE in 
the present study may have had low intestinal muco-
sal concentrations of glucagon-like peptide-2, which 
may have contributed to impaired intestinal protection 
against and repair following mucosal damage.
Fatty acids have an important role in inflammatory 
processes via nutritional and protective effects on en-
terocytes.36 Results of another study9 indicate that genes 
involved in expression of fatty acid transport, fatty acid 
binding, fatty acid acetylation, and fatty acid synthesis 
proteins are downregulated in ileal and colonic tissues 
of humans with CD and UC. Findings of the present 
study that expression of fatty acid–binding protein 6 
and fatty acid synthase were 13-fold and 3-fold as low, 
respectively, in intestinal mucosal biopsy specimens ob-
tained from dogs with CE as in biopsy specimens ob-
tained from healthy control dogs indicated dogs with 
CE had alterations in fatty acid metabolism similar to 
those detected in humans with IBD.
Intestinal epithelial barrier function is impaired in 
animals with IBD.13,37,38 Expression of several genes as-
sociated with maintenance of the intestinal epithelial 
barrier, including metallothionein 1E, metallothionein 
2A, and claudin 8, was downregulated in dogs with CE 
in the present study. Metallothioneins play a central role 
in zinc homeostasis, modulate activation of the nuclear 
transcription factor NF-κB, and serve as antioxidants to 
reduce intestinal inflammation.39,40 Claudins are a fam-
ily of proteins that contribute to intestinal barrier func-
tion as components of tight junction strands between 
intestinal epithelial cells.41 Changes in expression and 
distribution of claudin 8 have been detected in hu-
mans with active CD and lead to altered tight junction 
structure and barrier dysfunction.42 Results of other 
studies43,44 indicate expression of matrix metallopepti-
dases in intestinal mucosa of IBD patients is a marker 
of disease activity, and these enzymes may be targets 
for treatment. Matrix metallopeptidases are involved 
in tissue remodeling, angiogenesis, and leukocyte ex-
travasation in inflamed intestinal mucosa in humans 
with CD or UC.45 Many of the matrix metallopeptidases 
investigated in those studies were also upregulated in 
dogs with CE in the present study, in particular matrix 
metallopeptidases 1, 3, and 13.
Numerous immune and inflammatory response 
genes were upregulated in dogs with CE in the pres-
ent study. Members of the S100 calcium-binding pro-
tein family of genes are overexpressed in humans with 
IBD,8 and higher expression of S100 calcium-binding 
protein G, S100 calcium-binding protein A2, and S100 
calcium-binding protein A10 was detected in dogs with 
CE versus healthy control dogs in the present study. 
Moreover, expression of carcinoembryonic antigen– 
related cell adhesion molecule 18 (a marker of neutro-
phil activation and regulator of T-cell function) was 
also increased in dogs with CE, which suggested that 
there was infiltration of neutrophils in intestinal le-
sions, possibly in response to intestinal microbes.46 The 
peroxisome proliferator–activated receptor γ gene en-
codes for a nuclear hormone receptor that regulates in-
testinal inflammation via antagonism of the transcrip-
tion factor NF-κB.47 Peroxisome proliferator–activated 
receptor γ is highly expressed in a variety of cell types 
involved in intestinal inflammation, including mono-
cytes, macrophages, T cells, dendritic cells, and intes-
tinal epithelial cells. Increased epithelial expression of 
this protein is associated with attenuation of inflamma-
tory intestinal lesions in experimentally induced IBD in 
mice.48 It is possible that upregulated expression of this 
gene in dogs with CE in the present study was attrib-
utable to a compensatory response to chronic mucosal 
inflammation.
The finding of the present study that the caspase 3 
and granzyme B genes were overexpressed in dogs with 
CE indicated that apoptotic mechanisms may have been 
involved in pathogenesis of the disease in those dogs. 
Resistance of T cells against apoptosis may contribute 
to persistent intestinal inflammation in humans with 
IBD.49 Granzyme B is a serine protease that is an impor-
tant mediator of apoptosis of cells targeted by natural 
killer cells and cytotoxic CD8+ lymphocytes. The pri-
mary apoptotic mechanism of action of granzymes is 
perforin-mediated cytotoxicity.50 Further investigation 
of the mechanisms controlling mucosal lymphocyte 
apoptosis in dogs with CE is warranted.
Several organic cation transporter genes, including 
solute carrier family 40 member 1 and solute carrier 
family 2, member 2 (SLC2A2) were overexpressed in 
dogs with CE in the present study. Solute carrier mem-
brane transport proteins are diverse, are expressed 
in most mammalian cells, and transport charged and 
uncharged organic molecules and inorganic ions. 
Solute carrier family 40 member 1 is involved in ba-
solateral iron transport, and members of solute car-
rier family 2 SLC2, which includes 14 proteins, are 
facilitated glucose transporters.51 Other organic cation 
transporter genes (solute carrier family 22, member 4 
[SLC22A4], also known as organic cation transporter 
gene 1 [OCTN1]; and solute carrier family 22, member 5 
[SLC22A5], also known as organic cation transporter 
gene 2 [OCTN2]) are expressed in epithelial cells and 
have been implicated in CD.52
The present study had some limitations. Gene ex-
pression was assessed in mucosal biopsy specimens 
obtained at only 1 time from each dog; results pro-
vided evidence that expression of genes in dogs with 
CE was different from that in healthy control dogs only 
at the time CE was diagnosed. Results of future stud-
ies in which mucosal gene expression is determined at 
multiple times after diagnosis of CE in dogs may better 
elucidate the importance of specific patterns of gene ex-
pression in onset and progression of the disease. Also, 
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several of the significant differences in expression of 
genes between dogs with CE and healthy control dogs 
in the present study may be attributable to secondary, 
rather than primary, abnormalities of gene expression 
related to pathogenesis of CE. We chose to include a 
group of control dogs with no signs of gastroenteritis 
that were younger than the dogs with CE. The strict 
inclusion criteria for control dogs in the present study 
(dogs that were free of disease and had unremarkable 
results of diagnostic tests) resulted in inclusion of a 
small number of such dogs. However, inclusion of 
healthy control dogs of mixed breeds was considered 
preferable to inclusion of age-matched Beagles bred for 
use in research; such Beagles sometimes have evidence 
of intestinal disease.53 Therefore, it is possible that some 
of the differences in gene expression were attributable 
to differences in age between the 2 groups of dogs. Nev-
ertheless, the tissue sampling and microchip array anal-
ysis methods used in the present study yielded results 
that indicated patterns of gene expression in dogs with 
CE were broadly similar to those in humans with IBD, 
including expression of genes regulating immune and 
inflammatory responses, metabolism, cell proliferation, 
and epithelial structure and function.8,54–62
Results of the present study indicated that the ex-
pression of multiple genes regulating mucosal inflam-
mation was markedly altered in dogs with CE, com-
pared with that in healthy control dogs. The differential 
expression of several genes (fatty acid–binding protein 
6, metallothionein 1E, claudin 8, matrix metallopep-
tidase 1, peroxisome proliferator–activated receptor 
γ, S100 calcium-binding protein G, and solute carrier 
family 40 member 1) between groups of dogs in the 
present study indicated that the molecular pathogen-
esis of CE in dogs may be similar to that in chronic 
immune-mediated intestinal inflammation in humans 
with IBD. Future experiments that include dogs with 
naturally developing IBD may be warranted because ge-
nomic sequences of dogs and humans are highly simi-
lar63 and longitudinal studies (eg, clinical trials) might 
be easily conducted.
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   GenBank
Gene Primer Probe sequence (5′ to 3′) accession No.
Granzyme B Forward TGT TAX TGC TGC TTG AGA GGA AGG NC_006590
 Reverse ACC TGC GTA TCT TGG CCT CAA TCT 
Glucuronidase β Forward ATG CTG GTC CAG AGC TAC AGC AAT NC_006588
 Reverse ATG GGT GAT TCT TAT CCC GAC GCA 
ANP 32 family member A Forward AAC AGG ACG CCC TCT GAT GTG AAA NC_006612
 Reverse TGA GGT GAG GCC TAC GTT GAT TGT 
Chloride channel 3 Forward AGA AGG TCC TGG CTC GTA CAT CAT NC_006607
 Reverse CCA GGG AAA CAG CAA GAA AGG CAA 
MMP13 Forward GAC AGA TTC TTC TGG CGA TTG CAT CC NC_006587
 Reverse TAT GCA GCA TCG ATA CGG TTG GGA 
Caspase 3 Forward ATT ATT CAG GCC TGC CGA GGT ACA NC_006598
 Reverse TAC AAG AAG TCC GCT TCG ACT GGT 
Fibrillarin Forward TGC TCA TAG CAA TGG TGG ACG TGA NC_006583
 Reverse TAC GAA GGA AGG TGT GGG CAT TCA 
Appendix
Primer sequences used for QRT-PCR amplification of mRNA of various genes in intestinal mucosal 
biopsy samples endoscopically obtained from 18 dogs with CE and 6 healthy control dogs.
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